Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy
Proliferative diabetic retinopathy poses a major public health burden with panretinal photocoagulation the only standard of care. Given the recent studies demonstrating the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy for treating diabetic macular edema, pharmacotherapy ma...
Gespeichert in:
| Veröffentlicht in: | Current ophthalmology reports 2014-12, Vol.2 (4), p.175-183 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 183 |
|---|---|
| container_issue | 4 |
| container_start_page | 175 |
| container_title | Current ophthalmology reports |
| container_volume | 2 |
| creator | Flamendorf, Jason Fine, Howard F. |
| description | Proliferative diabetic retinopathy poses a major public health burden with panretinal photocoagulation the only standard of care. Given the recent studies demonstrating the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy for treating diabetic macular edema, pharmacotherapy may also be useful for prevention and treatment of proliferative diabetic retinopathy. Anti-VEGF therapy shows the greatest promise with its ability to delay retinopathy progression and even lead to improvements in disease severity. Furthermore, it may be useful for inducing regression of retinal and iris neovascularization. Corticosteroids, tetracyclines, and ocriplasmin are other treatments that have been considered. Additional randomized controlled trials are needed to support routine use of pharmacotherapy for specific indications in patients with proliferative diabetic retinopathy. |
| doi_str_mv | 10.1007/s40135-014-0053-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2933661733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2933661733</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2265-4ca805a533f0f888091175e804f5ac550ba50c13896f5902b1112d6afbe130cb3</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMoWGp_gLsB16P3JpNMZin1UaFgKXUdMmlip7STMZkW-u9NGUE33sV9wDnnwkfILcI9ApQPsQBkPAcscgDOcn5BRhRFmRdSyMs_-zWZxLiFVJIKkDgiy8VGh702vt_YoLtT5nzIVsHqfm_bPtPtOlsEe0x749vMu3T5XeOStm-ONntqdG37xmTL1Fvf6X5zuiFXTu-infzMMfl4eV5NZ_n8_fVt-jjPDaWC54XRErjmjDlwUkqoEEtuJRSOa8M51JqDQSYr4XgFtEZEuhba1RYZmJqNyd2Q2wX_dbCxV1t_CG16qWjFmBBYMpZUOKhM8DEG61QXmr0OJ4WgzvTUQE8leupMT_HkoYMnJm37acNv8v-mb-SycVM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2933661733</pqid></control><display><type>article</type><title>Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy</title><source>Springer Nature - Complete Springer Journals</source><source>ProQuest Central</source><creator>Flamendorf, Jason ; Fine, Howard F.</creator><creatorcontrib>Flamendorf, Jason ; Fine, Howard F.</creatorcontrib><description>Proliferative diabetic retinopathy poses a major public health burden with panretinal photocoagulation the only standard of care. Given the recent studies demonstrating the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy for treating diabetic macular edema, pharmacotherapy may also be useful for prevention and treatment of proliferative diabetic retinopathy. Anti-VEGF therapy shows the greatest promise with its ability to delay retinopathy progression and even lead to improvements in disease severity. Furthermore, it may be useful for inducing regression of retinal and iris neovascularization. Corticosteroids, tetracyclines, and ocriplasmin are other treatments that have been considered. Additional randomized controlled trials are needed to support routine use of pharmacotherapy for specific indications in patients with proliferative diabetic retinopathy.</description><identifier>ISSN: 2167-4868</identifier><identifier>EISSN: 2167-4868</identifier><identifier>DOI: 10.1007/s40135-014-0053-5</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Clinical trials ; Diabetes ; Diabetic retinopathy ; Diabetic Retinopathy: Medical and Surgical Therapies (S. Kiss ; Drug therapy ; Edema ; Iris ; Lasers ; Medicine ; Medicine & Public Health ; Ophthalmology ; Section Editor ; Vascular endothelial growth factor</subject><ispartof>Current ophthalmology reports, 2014-12, Vol.2 (4), p.175-183</ispartof><rights>Springer Science + Business Media New York 2014</rights><rights>Springer Science + Business Media New York 2014.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2265-4ca805a533f0f888091175e804f5ac550ba50c13896f5902b1112d6afbe130cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40135-014-0053-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2933661733?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,21367,27901,27902,33721,41464,42533,43781,51294</link.rule.ids></links><search><creatorcontrib>Flamendorf, Jason</creatorcontrib><creatorcontrib>Fine, Howard F.</creatorcontrib><title>Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy</title><title>Current ophthalmology reports</title><addtitle>Curr Ophthalmol Rep</addtitle><description>Proliferative diabetic retinopathy poses a major public health burden with panretinal photocoagulation the only standard of care. Given the recent studies demonstrating the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy for treating diabetic macular edema, pharmacotherapy may also be useful for prevention and treatment of proliferative diabetic retinopathy. Anti-VEGF therapy shows the greatest promise with its ability to delay retinopathy progression and even lead to improvements in disease severity. Furthermore, it may be useful for inducing regression of retinal and iris neovascularization. Corticosteroids, tetracyclines, and ocriplasmin are other treatments that have been considered. Additional randomized controlled trials are needed to support routine use of pharmacotherapy for specific indications in patients with proliferative diabetic retinopathy.</description><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy: Medical and Surgical Therapies (S. Kiss</subject><subject>Drug therapy</subject><subject>Edema</subject><subject>Iris</subject><subject>Lasers</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Section Editor</subject><subject>Vascular endothelial growth factor</subject><issn>2167-4868</issn><issn>2167-4868</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1kEtLAzEUhYMoWGp_gLsB16P3JpNMZin1UaFgKXUdMmlip7STMZkW-u9NGUE33sV9wDnnwkfILcI9ApQPsQBkPAcscgDOcn5BRhRFmRdSyMs_-zWZxLiFVJIKkDgiy8VGh702vt_YoLtT5nzIVsHqfm_bPtPtOlsEe0x749vMu3T5XeOStm-ONntqdG37xmTL1Fvf6X5zuiFXTu-infzMMfl4eV5NZ_n8_fVt-jjPDaWC54XRErjmjDlwUkqoEEtuJRSOa8M51JqDQSYr4XgFtEZEuhba1RYZmJqNyd2Q2wX_dbCxV1t_CG16qWjFmBBYMpZUOKhM8DEG61QXmr0OJ4WgzvTUQE8leupMT_HkoYMnJm37acNv8v-mb-SycVM</recordid><startdate>20141201</startdate><enddate>20141201</enddate><creator>Flamendorf, Jason</creator><creator>Fine, Howard F.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20141201</creationdate><title>Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy</title><author>Flamendorf, Jason ; Fine, Howard F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2265-4ca805a533f0f888091175e804f5ac550ba50c13896f5902b1112d6afbe130cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy: Medical and Surgical Therapies (S. Kiss</topic><topic>Drug therapy</topic><topic>Edema</topic><topic>Iris</topic><topic>Lasers</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Section Editor</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Flamendorf, Jason</creatorcontrib><creatorcontrib>Fine, Howard F.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Current ophthalmology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Flamendorf, Jason</au><au>Fine, Howard F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy</atitle><jtitle>Current ophthalmology reports</jtitle><stitle>Curr Ophthalmol Rep</stitle><date>2014-12-01</date><risdate>2014</risdate><volume>2</volume><issue>4</issue><spage>175</spage><epage>183</epage><pages>175-183</pages><issn>2167-4868</issn><eissn>2167-4868</eissn><abstract>Proliferative diabetic retinopathy poses a major public health burden with panretinal photocoagulation the only standard of care. Given the recent studies demonstrating the effectiveness of anti-vascular endothelial growth factor (VEGF) therapy for treating diabetic macular edema, pharmacotherapy may also be useful for prevention and treatment of proliferative diabetic retinopathy. Anti-VEGF therapy shows the greatest promise with its ability to delay retinopathy progression and even lead to improvements in disease severity. Furthermore, it may be useful for inducing regression of retinal and iris neovascularization. Corticosteroids, tetracyclines, and ocriplasmin are other treatments that have been considered. Additional randomized controlled trials are needed to support routine use of pharmacotherapy for specific indications in patients with proliferative diabetic retinopathy.</abstract><cop>Boston</cop><pub>Springer US</pub><doi>10.1007/s40135-014-0053-5</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2167-4868 |
| ispartof | Current ophthalmology reports, 2014-12, Vol.2 (4), p.175-183 |
| issn | 2167-4868 2167-4868 |
| language | eng |
| recordid | cdi_proquest_journals_2933661733 |
| source | Springer Nature - Complete Springer Journals; ProQuest Central |
| subjects | Clinical trials Diabetes Diabetic retinopathy Diabetic Retinopathy: Medical and Surgical Therapies (S. Kiss Drug therapy Edema Iris Lasers Medicine Medicine & Public Health Ophthalmology Section Editor Vascular endothelial growth factor |
| title | Pharmacotherapy for Treatment and Prevention of Proliferative Diabetic Retinopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T20%3A02%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacotherapy%20for%20Treatment%20and%20Prevention%20of%20Proliferative%20Diabetic%20Retinopathy&rft.jtitle=Current%20ophthalmology%20reports&rft.au=Flamendorf,%20Jason&rft.date=2014-12-01&rft.volume=2&rft.issue=4&rft.spage=175&rft.epage=183&rft.pages=175-183&rft.issn=2167-4868&rft.eissn=2167-4868&rft_id=info:doi/10.1007/s40135-014-0053-5&rft_dat=%3Cproquest_cross%3E2933661733%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2933661733&rft_id=info:pmid/&rfr_iscdi=true |